Literature DB >> 12164960

Fusobacterium varium localized in the colonic mucosa of patients with ulcerative colitis stimulates species-specific antibody.

Toshifumi Ohkusa1, Nobuhiro Sato, Tatuo Ogihara, Koji Morita, Masayuki Ogawa, Isao Okayasu.   

Abstract

BACKGROUND: Microbial agents are a possible cause of ulcerative colitis. We have previously reported evidence of bacteria invading the colonic mucosa of patients with ulcerative colitis. We have isolated bacteria from inflamed colonic mucosa, examined the localization of the species in the mucosa, and assayed for serum antibodies to the bacteria.
METHODS: Cohorts of 31 per group were enrolled from patients with active ulcerative colitis, Crohn's disease, ischemic colitis, and colon adenomas. A group of 31 healthy controls were also studied. The presence of bacteria in biopsies of patients with ulcerative colitis was analyzed by both isolation and immunohistochemistry. Sera from patients were tested for bacterial antibodies using both Western blots and enzyme-linked immunosorbent assay (ELISA).
RESULTS: Only sera from patients with ulcerative colitis gave specific reactions with Fusobacterium varium in Western blot assays. The detection rate of specific bands was higher for patients with ulcerative colitis (61%) than for subjects with either Crohn's disease (13%) or healthy controls (29%) (P < 0.001 and P = 0.021, respectively). The ELISA showed that the mean optical densities with extracts of F. varium as antigen were significantly higher for ulcerative colitis patients than for subjects with either Crohn's disease or healthy controls (P < 0.001). Immunohistochemical detection of F. varium in colonic mucosa was significantly higher in patients with ulcerative colitis (84%) than for subjects with either Crohn's disease (16%) or other controls (3-13%) (P < 0.001).
CONCLUSIONS: Fusobacterium varium bacteria were present in a significant number of patients with active ulcerative colitis, and should be tested in therapeutic trials in order to confirm the causal relationship between F. varium and ulcerative colitis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12164960     DOI: 10.1046/j.1440-1746.2002.02834.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  72 in total

1.  Reduced diversity and imbalance of fecal microbiota in patients with ulcerative colitis.

Authors:  Hideyuki Nemoto; Keiko Kataoka; Hideki Ishikawa; Kazue Ikata; Hideki Arimochi; Teruaki Iwasaki; Yoshinari Ohnishi; Tomomi Kuwahara; Koji Yasutomo
Journal:  Dig Dis Sci       Date:  2012-05-24       Impact factor: 3.199

2.  Genomic analysis identifies association of Fusobacterium with colorectal carcinoma.

Authors:  Aleksandar D Kostic; Dirk Gevers; Chandra Sekhar Pedamallu; Monia Michaud; Fujiko Duke; Ashlee M Earl; Akinyemi I Ojesina; Joonil Jung; Adam J Bass; Josep Tabernero; José Baselga; Chen Liu; Ramesh A Shivdasani; Shuji Ogino; Bruce W Birren; Curtis Huttenhower; Wendy S Garrett; Matthew Meyerson
Journal:  Genome Res       Date:  2011-10-18       Impact factor: 9.043

Review 3.  What is the origin of ulcerative colitis? Still more questions than answers.

Authors:  Milan Lukas; Martin Bortlik; Zdenek Maratka
Journal:  Postgrad Med J       Date:  2006-10       Impact factor: 2.401

4.  Fusobacterium in colonic flora and molecular features of colorectal carcinoma.

Authors:  Tomomitsu Tahara; Eiichiro Yamamoto; Hiromu Suzuki; Reo Maruyama; Woonbok Chung; Judith Garriga; Jaroslav Jelinek; Hiro-o Yamano; Tamotsu Sugai; Byonggu An; Imad Shureiqi; Minoru Toyota; Yutaka Kondo; Marcos R H Estécio; Jean-Pierre J Issa
Journal:  Cancer Res       Date:  2014-01-02       Impact factor: 12.701

Review 5.  Current State of Knowledge on Implications of Gut Microbiome for Surgical Conditions.

Authors:  Edmund B Chen; Cori Cason; Jack A Gilbert; Karen J Ho
Journal:  J Gastrointest Surg       Date:  2018-04-05       Impact factor: 3.452

Review 6.  A breakthrough in probiotics: Clostridium butyricum regulates gut homeostasis and anti-inflammatory response in inflammatory bowel disease.

Authors:  Takanori Kanai; Yohei Mikami; Atsushi Hayashi
Journal:  J Gastroenterol       Date:  2015-05-05       Impact factor: 7.527

Review 7.  The microbiota in inflammatory bowel disease.

Authors:  Donal Sheehan; Carthage Moran; Fergus Shanahan
Journal:  J Gastroenterol       Date:  2015-03-26       Impact factor: 7.527

Review 8.  The gut microbiome: what every gastroenterologist needs to know.

Authors:  Benjamin H Mullish; Mohammed Nabil Quraishi; Jonathan P Segal; Gianluca Ianiro; Tariq H Iqbal
Journal:  Frontline Gastroenterol       Date:  2020-02-04

9.  Dysbiosis in inflammatory bowel disease.

Authors:  C P Tamboli; C Neut; P Desreumaux; J F Colombel
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

Review 10.  The gut microbiota in IBD.

Authors:  Chaysavanh Manichanh; Natalia Borruel; Francesc Casellas; Francisco Guarner
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-08-21       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.